Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

Caring for someone living with HIV at home involves providing physical, emotional, and medical support to help them manage ...

Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...

Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.

"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...

Schulich School of Medicine & Dentistry researchers are on the cutting-edge of the study of HIV, working toward treatments ...

Telemedicine represents both an opportunity and a challenge. On the one hand, it offers transformative potential to address ...